Tuesday, June 28, 2011
Redwood Bioscience Inc., of Burlingame, Calif., secured an undisclosed amount of funding from Takeda Ventures Inc. to further develop its precision protein-chemical engineering platform for drug conjugate optimization. The money will advance Redwood's site-specific protein modification technology for enhancing antibody-drug conjugates and peptide therapeutics.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.